U.S. stock market movement: Iovance shares plunge on October 30 due to disappointing lung cancer data and low KRAS efficacy

Iovance October 30th Sharp Decline Analysis

Keywords: Poor lung cancer data, KRAS inefficacy

1. On October 29th, the company announced updated Phase II data from the IOV-LUN-202 trial. Among 69 non-squamous mNSCLC cases, the objective response rate was 24.6%, essentially consistent with the previous 25.6%, showing no improvement in overall efficacy. The ORR in the KRAS mutation subgroup was only 11.4%, lower than the 43.3% in the KRAS wild-type group and 59.1% in the biomarker-enriched subgroup. Data on duration of response and specific safety/tolerability results were not disclosed.

2. On October 29th, the company announced the POSITILITY study is planned to start in November 2026, and the sBLA is expected to be filed in 2027. There is a long time horizon before both registration and commercialization.

3. On October 29th, the stock price fell below the 50-day moving average. As of October 29th, the price had declined by 37.69% in the past five days but increased by 221.61% year to date, reflecting a pullback after a large previous gain. On the same day, a bearish position was opened in the 2029 call options at a strike price of $15, with a net premium of $950,000.

(Disclaimer: This content is summarized using AI technology from publicly available information and is for reference only. It does not constitute investment advice.)